← Back to Search

Anti-tumor antibiotic

BMS-247550 + Capecitabine for Breast Cancer

Phase 1

Waitlist Available

Research Sponsored by R-Pharm

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically or cytologically confirmed breast cancer

No dementia or altered mental status that would preclude study

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well BMS-247550 and capecitabine work in combination in treating patients with metastatic breast cancer.

Who is the study for?

This trial is for adults with metastatic breast cancer that didn't improve after treatment with taxane and anthracycline. Participants must not be pregnant, should use contraception if fertile, have no severe heart issues or infections, a life expectancy of at least 3 months, and acceptable blood counts and organ function.Check my eligibility

What is being tested?

The study tests the combination of BMS-247550 with capecitabine in patients whose metastatic breast cancer has resisted previous chemotherapy. It's a Phase I trial to see how effective this drug duo is against tumor cells.See study design

What are the potential side effects?

Potential side effects may include reactions related to chemotherapy such as nausea, fatigue, hair loss, low blood cell counts leading to increased infection risk or bleeding problems, liver issues indicated by abnormal blood tests, and possibly heart complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My breast cancer diagnosis was confirmed through lab tests.

Select...

My mental health allows me to participate in studies.

Select...

I do not have severe nerve damage.

Select...

I do not have any active cancer spread to my brain.

Select...

I am 18 years old or older.

Select...

My cancer can be measured or seen on tests.

Select...

My bone lesions cannot be measured.

Select...

My heart is healthy with no recent major issues or uncontrolled conditions.

Select...

My cancer has spread to other parts of my body, confirmed by scans or tissue samples.

Select...

I have been treated with taxane and anthracycline for my cancer.

Select...

I have had 2 or fewer chemotherapy treatments for cancer that has spread.

Select...

I am fully active or can carry out light work.

Select...

My kidney function, measured by creatinine, is within normal limits.

Select...

My liver tests are within the required limits.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 14Eligibility criteria met

Find a Location

Who is running the clinical trial?

R-PharmLead Sponsor

58 Previous Clinical Trials

14,210 Total Patients Enrolled

4 Trials studying Breast Cancer

2,107 Patients Enrolled for Breast Cancer

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,153 Total Patients Enrolled

939 Trials studying Breast Cancer

1,543,360 Patients Enrolled for Breast Cancer

Linnea Chap, MDStudy ChairJonsson Comprehensive Cancer Center

3 Previous Clinical Trials

298 Total Patients Enrolled

2 Trials studying Breast Cancer

298 Patients Enrolled for Breast Cancer

Media Library

BMS-247550 (Anti-tumor antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT00049244 — Phase 1

Breast Cancer Clinical Trial 2023: BMS-247550 Highlights & Side Effects. Trial Name: NCT00049244 — Phase 1

BMS-247550 (Anti-tumor antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00049244 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open slots available for participation in this clinical trial?

"Interestingly, clinicaltrials.gov does not indicate that this trial is currently enrolling patients. Its original post date was September 1st 2002 and the last update was January 27th 2017; however, there are 2600 additional medical studies actively recruiting volunteers at present time."

Answered by AI

Is this therapy acclaimed for its safety by medical professionals?

"The safety of this treatment is rated a 1, since it is still in its first trial phase and there are limited data confirming efficacy or establishing security."

Answered by AI